NASHVILLE, Tenn. & PRINCETON, N.J.--(BUSINESS WIRE)--The School of Global Health at Meharry Medical College (Meharry) with support from Otsuka America Pharmaceutical, Inc., today released The Projected Costs and Economic Impact of Mental Health Inequities in the United States report. Findings show, that if not addressed, mental health inequities combined with expenditures related to chronic conditions, could cost the U.S.

田纳西州纳什维尔和新泽西州普林斯顿——（商业新闻短讯）——在大冢美国制药公司的支持下，梅哈里医学院（Meharry）全球健康学院今天在美国报告中公布了心理健康不平等的预计成本和经济影响。调查结果表明，如果不加以解决，心理健康不平等以及与慢性病相关的支出可能会使美国付出代价。

economy an estimated $14 trillion between now and 2040..

从现在到2040年，经济规模估计为14万亿美元。。

According to the Meharry analysis, the U.S. currently spends an estimated $477.5 billion annually in avoidable and unnecessary expenses related to mental health inequities, or disparate outcomes in quality and access to care across communities. This excess spending is expected to grow to $1.3 trillion annually by 2040.

根据Meharry的分析，美国目前每年估计花费4775亿美元，用于与心理健康不平等或社区质量和获得护理的不同结果相关的可避免和不必要的费用。预计到2040年，这一超额支出每年将增长至1.3万亿美元。

Lower-income individuals and minority populations bear a disproportionate burden of both mental health and chronic conditions, which are intrinsically connected, exacerbating the economic challenges they face and contributing to continued productivity loss. The report found that mental health conditions greatly impact the trajectory of other chronic diseases in America, including cardiovascular disease, diabetes, and HIV.

低收入个人和少数民族人口承受着心理健康和慢性病的不成比例的负担，这两者有着内在的联系，加剧了他们面临的经济挑战，并导致生产力持续下降。报告发现，心理健康状况极大地影响了美国其他慢性疾病的发展轨迹，包括心血管疾病、糖尿病和艾滋病毒。

By 2040, the effects of care inequities will only increase..

到2040年，护理不公平的影响只会增加。。

This report builds on landmark findings of The Economic Burden of Mental Health Inequities in the United States report released in 2022, which showed over a four-year period (2016-2020) at minimum, nearly 117,000 lives and approximately $278 billion could have been saved with proper investment in mental healthcare for marginalized and underserved populations.

本报告基于2022年发布的美国报告中关于心理健康不平等经济负担的里程碑式发现，该报告显示，在至少四年（2016-2020年）的时间内，通过对边缘化和服务不足人群的心理保健进行适当投资，可以挽救近117000条生命和约2780亿美元。

In the latest report, Meharry takes this further to investigate how existing inequities in mental health treatment will overwhelm the American healthcare system if left unaddressed..

在最新的报告中，梅哈里进一步调查了如果不加以解决，心理健康治疗中存在的不公平现象将如何压倒美国医疗体系。。

“In our first report, tangible evidence demonstrated how decades of systemic health inequities have yielded significantly worse outcomes for minority populations,” said Daniel Dawes, founding dean and senior vice president of the Meharry School of Global Health and author of the Political Determinants of Health.

“在我们的第一份报告中，有确凿的证据表明，数十年来的系统性健康不平等给少数民族人口带来了明显更糟糕的结果，”梅哈里全球健康学院创始院长兼高级副院长、《健康的政治决定因素》一书的作者丹尼尔·道斯说。

“This latest study shows the critical urgency around the mental health crisis in the U.S. and monetizes the magnitude of neglect. If we don’t act, mental health inequities will cost the U.S. economy trillions over the next two decades.”.

“这项最新研究表明，围绕美国心理健康危机的紧迫性，并将忽视的程度货币化。如果我们不采取行动，心理健康不平等将在未来二十年内使美国经济损失数万亿美元。”。

The report assessed 10 expenditures across four categories – chronic conditions, premature death, emergency department utilization, and productivity loss – to predict the excess costs arising from mental health inequities. The report analyzed disparities of care for patients across various racial and ethnic backgrounds, socioeconomic status and age, analyzing disparities as they related to each of the four main health categories.

该报告评估了慢性病、过早死亡、急诊科利用率和生产力损失四个类别的10项支出，以预测心理健康不公平产生的超额成本。该报告分析了不同种族和民族背景，社会经济地位和年龄的患者护理差异，分析了与四个主要健康类别相关的差异。

Researchers analyzed data from multiple sources, including the Centers for Disease Control and Prevention’s WONDER database and Komodo’s Healthcare Map, that allowed them to develop a new approach to quantify productivity lost because of these mental health inequities. This report should be considered a catalyst for additional research into subpopulations not included in the report, including gender and sexual orientation..

研究人员分析了来自多个来源的数据，包括疾病控制和预防中心的WONDER数据库和Komodo的医疗保健地图，这使他们能够开发一种新方法来量化由于这些心理健康不平等而导致的生产力损失。该报告应被视为对报告中未包括的亚人群（包括性别和性取向）进行进一步研究的催化剂。。

“This sobering research by the School of Global Health Meharry Medical College continues to shine a bright light on the enormous economic and social challenges that the acute mental health crisis in America represents. This is especially true for minority populations that find it harder to access proper healthcare,” said Tarek Rabah, president and CEO, Otsuka North America Pharmaceutical Business.

大冢北美制药公司总裁兼首席执行官塔瑞克·拉巴（Tarek Rabah）表示：“梅哈里医学院全球健康学院（School of Global Health Meharry Medical College）的这项令人清醒的研究继续为美国严重的心理健康危机所代表的巨大经济和社会挑战提供了光明的前景。对于那些难以获得适当医疗保健的少数民族人群来说尤其如此。”。

“As a country, we must address head on the mental health inequities that are causing massive human and economic burden. Through our continued support of important research like this latest report, Otsuka is continuing our commitment to working with stakeholders in the mental health community to help rebuild our mental healthcare system with the hope of offering a more integrated, equitable experience for anyone seeking care in the future.”.

“作为一个国家，我们必须直面造成巨大人力和经济负担的心理健康不平等问题。通过我们对最新报告等重要研究的持续支持，大冢继续致力于与心理健康界的利益相关者合作，帮助重建我们的心理保健系统，希望为未来寻求护理的任何人提供更全面，更公平的体验。”。

The findings of this report highlight the need for policy changes in the U.S. healthcare system, including increasing access to mental health care and driving models which seek to recognize and fully integrate physical and mental health conditions. Policymakers may use this research as a roadmap to design new legislation that addresses gaps in care.

本报告的调查结果强调了美国医疗保健系统政策变化的必要性，包括增加获得心理保健的机会，以及寻求认识和充分整合身心健康状况的驾驶模式。政策制定者可能会将这项研究用作路线图，以设计解决护理差距的新立法。

The Meharry School of Global Health offers the following cross-sector approach for federal and state policymakers who work closely with the private sector and academia:.

梅哈里全球卫生学院为与私营部门和学术界密切合作的联邦和州决策者提供了以下跨部门方法：。

Congress and federal policymakers should continue to strengthen and enforce mental health parity provisions to ensure better coverage for mental health treatments and incentivize regular mental health screenings.

国会和联邦政策制定者应继续加强和执行心理健康均等条款，以确保更好地覆盖心理健康治疗，并鼓励定期进行心理健康筛查。

Congress, along with state and federal health agencies, should assess how existing reimbursement and coverage policies may create unintended barriers to treatment for those struggling to access the broader healthcare system.

国会，以及州和联邦卫生机构，应该评估现有的报销和覆盖政策如何为那些难以进入更广泛的医疗保健系统的人造成意外的治疗障碍。

Academia should partner with policymakers to collaborate on workforce-focused initiatives designed to build a larger and more diverse workforce for mental health providers across the continuum.

学术界应该与政策制定者合作，开展以劳动力为重点的举措，旨在为整个连续体的心理健康提供者建立更大、更多样化的劳动力队伍。

Local governments should incentivize mental health providers to join their communities, execute programs to drive awareness and access and other critical resources to the places where they are most needed and least found.

地方政府应鼓励心理健康提供者加入他们的社区，执行项目以提高认识，并将其他关键资源提供给他们最需要和最不容易找到的地方。

To read the report, please click here.

要阅读报告，请单击此处。

About Otsuka Pharmaceutical

关于大冢制药

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health..

大冢制药有限公司是一家全球性的医疗保健公司，其企业理念是：大冢-人们创造新产品以改善全球健康。大冢研究、开发、制造和销售创新产品，重点是满足未满足医疗需求的医药产品和维持日常健康的营养保健产品。。

In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does..

在制药领域，大冢在精神、肾脏和心血管健康等具有挑战性的领域处于领先地位，并在肿瘤学和包括结核病（一个重要的全球公共卫生问题）在内的一些未得到充分解决的疾病方面拥有额外的研究项目。这些承诺说明大冢在本质上是一家“大风险”公司，在其所做的每件事中都运用了年轻的创造力。。

Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs..

大冢于1973年在美国成立了分支机构，如今其美国分支机构包括大冢制药开发与商业化公司（OPDC）和大冢美国制药公司（OAPI）。这两家公司在美国的2250名员工利用尖端技术开发心理健康和肾脏病领域的药物并将其商业化，以解决未满足的医疗保健需求。。

OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 34,400 people worldwide and had consolidated sales of approximately USD 14.2 billion in 2023.

OPDC和OAPI是大冢制药有限公司的间接子公司，大冢制药有限公司是大冢控股有限公司的子公司，总部位于日本东京。大冢集团在全球拥有34400名员工，2023年的合并销售额约为142亿美元。

All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at https://www.otsuka.co.jp/en/.

所有大冢的故事都是从走人迹罕至的路开始的。有关大冢在美国的更多信息，请访问www.Otsuka-us.com，并通过LinkedIn和Twitter@OtsukaUS与我们联系。大冢制药有限公司的全球网站可访问https://www.otsuka.co.jp/en/.

About the School of Global Health at Meharry Medical College

关于梅哈里医学院全球健康学院

The School of Global Health at Meharry Medical College, located in Nashville, Tennessee, is rooted in Meharry’s nearly 150-year legacy of leading on health equity issues. As the nation’s first and only School of Global Health we are committed to preparing the next generation of global health learners and leaders to find solutions and respond to our communities’ complex and evolving health challenges with a global perspective.

位于田纳西州纳什维尔的梅哈里医学院全球健康学院植根于梅哈里在健康公平问题上领导近150年的传统。作为美国第一所也是唯一一所全球健康学校，我们致力于培养下一代全球健康学习者和领导者，以全球视角寻找解决方案，应对我们社区复杂而不断变化的健康挑战。

A hub for research and academic innovation in global health, mental and behavioral health, population health, public health, environmental health, health communications, social and political determinants of health, and more, the School is a trusted resource for health equity approaches and actionable solutions to the inequities affecting our most vulnerable, under-resourced, and marginalized communities.

该校是全球健康、心理和行为健康、人口健康、公共健康、环境健康、健康传播、健康的社会和政治决定因素等领域的研究和学术创新中心，是健康公平方法和可行解决方案的可靠资源，可以解决影响我们最脆弱、资源不足和边缘化社区的不公平现象。

Learn more at MeharryGlobal.org..

更多信息，请访问MeharryGlobal.org。。